New brain cancer strategy: wake up immune system before surgery
NCT ID NCT05423210
Summary
This small, early-stage study is testing a new approach for treating glioblastoma, an aggressive brain cancer. Researchers want to see if giving a short course of targeted radiation along with an immunotherapy drug (atezolizumab) *before* surgery can help the patient's own immune system better recognize and attack the tumor. After this initial treatment, patients will have standard surgery and then continue receiving the immunotherapy drug as part of their ongoing care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stony Brook University Hospital
RECRUITINGStony Brook, New York, 11794, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.